IN A CLINICAL TRIAL
UPTRAVI® reduced the risk of PAH disease progression* by 40%.1
27% of patients treated with UPTRAVI® experienced a PAH disease progression event vs 41.6% of
patients not taking UPTRAVI®.1
UPTRAVI® reduced the risk of PAH-related hospitalizations. This benefit was demonstrated in a
clinical trial comparing patients taking UPTRAVI® to those not taking UPTRAVI®. Patients took UPTRAVI® for an
average of 1.4 years.1
In this same clinical trial, patients taking UPTRAVI® walked an average of 12 meters (about
39 feet) farther than patients not taking UPTRAVI®, as measured by the 6-minute walk distance
(6MWD).1
*In a clinical trial of UPTRAVI®, PAH disease progression was defined as a serious event,
such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy;
lung transplantation; a decline in 6-minute walk distance (6MWD) combined with worsening of functional class
(FC) or need for additional PAH therapy; or death.
How the study was conducted:
UPTRAVI® was studied in the largest trial of any
FDA-approved PAH treatment1
- The trial included 1156 total PAH patients.
-
Compared 574 patients taking UPTRAVI® with 582 patients taking placebo (a sugar pill)
- 80% of enrolled patients were treated with an endothelin receptor antagonist (ERA),
phosphodiesterase type-5 inhibitor (PDE-5 inhibitor), or both for PAH
- 20% of enrolled patients were not on any PAH treatment
- Nearly all patients were FC II or FC III (PAH patients range from FC I to FC IV)
- Patients taking UPTRAVI® were treated for an average of 1.4 years during this study
- The trial included the most scleroderma-related PAH patients of any PAH trial (170 out of
1156)3,4